Previous 10 | Next 10 |
Check These 3 Penny Stocks Out For Your Watchlist As we end another week of trading penny stocks and blue chips, there is a lot for investors to keep in mind. Despite mostly positive sentiment as the week ended, penny stocks and blue chips have been in a blood bath in the past few m...
Topline data expected in December 2022 Full data from Phase I first-in-human study demonstrated AL001 in plasma is bioequivalent to the marketed lithium carbonate product Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early c...
BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“ BitNile ” or the “ Company ”) announced today its wholly owned subsidiary, Digital Power Lending, LLC (“ DP Lending ”) has made an additional investme...
Full data from Phase 1 first-in-human study demonstrate AL001 in plasma is bioequivalent to the marketed lithium carbonate product Alzamend planning to commence Phase 2A multiple ascending dose study in May 2022 Alzamend Neuro, Inc. (Nasdaq: ALZN) (...
Top Penny Stocks News on April 13th After Tuesday posed a bearish turnaround for penny stocks and blue chips at midday, investors are hopeful that Wednesday could be different. In the past few trading days, we’ve seen a sizable amount of volatility for penny stocks . This is ...
Antares Pharma ATRS +49% on ~$1B acquisition deal by Halozyme. Sierra Oncology SRRA +37% GSK to acquire Sierra Oncology for $1.9B to bolster specialty meds. BriaCell Therapeutics (BCTX) +17% receives FDA fast track approval for targeted breast cancer immunotherapy. Hi...
Alzamend Neuro (NASDAQ:ALZN) said it had tied up with contract research organizations Altasciences Clinical Kansas and iResearch Atlanta to manage and conduct its Phase II multiple ascending dose study in patients with mild to moderate Alzheimer’s disease. The Phase IIA study, whi...
Full Data Set from Phase I First-in-Human Helped Establish Doses for Phase IIA Multiple Ascending Dose Study Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products f...
MedAvail Holdings (MDVL) +38%. Aterian (ATER) +23%. Sunshine Biopharma SBFM +17% extends upswing to fourth consecutive day. Biofrontera BFRI +15% on Q4 results. System1 (SST) +13%. SeaChange International SEAC +11% on Q4 results. Lion Group Holding (LGHL) +8%. Zh...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter...
News, Short Squeeze, Breakout and More Instantly...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...